Detalhe da pesquisa
1.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
2.
A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia - the TEAM-ET 2·0 trial.
Br J Haematol
; 185(4): 691-700, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30919941
3.
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Lancet Haematol
; 10(10): e801-e812, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37793771
4.
Case of Non-Langerhans Cell Histiocytosis in a Person Living with HIV - Clinical and Therapeutic Challenge.
J Int Assoc Provid AIDS Care
; 21: 23259582221109567, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35775123
5.
Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Leukemia
; 35(12): 3455-3465, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34017073
6.
Nevus Blue as a Sporadic Finding in a Patient with a Blue Toe?
Open Access Maced J Med Sci
; 6(5): 855-858, 2018 May 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29875860
7.
A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS.
Leukemia
; 32(12): 2648-2658, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29895954
8.
Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
Leukemia
; 35(12): 3626, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34475521
9.
Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Leukemia
; 35(12): 3637, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34789825
10.
Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Leukemia
; 35(7): 2119-2124, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33483617